Related Experiment Video
Updated: Dec 6, 2025
06:44
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
13.8K
Predicting and Overcoming Taxane Chemoresistance
Sylvie Rodrigues-Ferreira1, Hadia Moindjie2, Maria M Haykal2
1Université Paris-Saclay, Institut Gustave Roussy, Inserm U981, Biomarqueurs prédictifs et nouvelles stratégies thérapeutiques en oncologie, 94800, Villejuif, France; LabEx LERMIT, Université Paris Saclay, 92296 Châtenay-Malabry, France; Inovarion, 75005 Paris, France.
Trends in Molecular Medicine
|October 13, 2020
Summary
Taxane resistance is a major challenge in cancer chemotherapy. New biomarkers and strategies targeting tumor metabolism and microenvironment are emerging to improve treatment outcomes.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Taxanes are crucial microtubule-targeting agents in cytotoxic chemotherapy for solid tumors.
- Therapeutic failure due to taxane resistance significantly impacts patient outcomes.
- Identifying predictive biomarkers is essential for patient stratification and optimizing taxane efficacy.
Purpose of the Study:
- To review recent advancements in understanding taxane resistance mechanisms.
- To explore emerging strategies for overcoming chemoresistance.
- To highlight the potential of personalized medicine in taxane-based therapies.
Main Methods:
- Literature review of recent research on taxane resistance.
- Analysis of novel resistance mechanisms, including metabolic reprogramming.
- Examination of tumor microenvironment interactions in chemoresistance.
Main Results:
- Taxane resistance is a complex multifactorial phenomenon.
- New insights reveal the role of metabolic reprogramming and tumor microenvironment.
- Biomarker discovery is advancing patient selection for taxane therapy.
Conclusions:
- Overcoming taxane resistance is critical for improving cancer treatment.
- Personalized medicine approaches, informed by biomarkers and novel mechanisms, offer future therapeutic avenues.
- Continued research into resistance pathways and microenvironment interactions is vital for developing effective strategies.
Keywords:
Taxolmetabolic reprogrammingmicrotubule targeting agentsmitotic defectspredictive biomarkertumor microenvironmentMore Related Videos
Related Concept Videos
02:56Treatment Resistant Cancers
3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
01:15Drugs that Stabilize Microtubules
2.4K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.4K
02:57Targeted Cancer Therapies
8.3K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.3K
02:40Cancer Stem Cells and Tumor Maintenance
5.7K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.7K
02:50Combination Therapies and Personalized Medicine
5.7K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.7K
02:53Adaptive Mechanisms in Cancer Cells
6.6K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.6K